Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Osimertinib in advanced non-small cell lung cancer (NSCLC) harboring different EGFR uncommon variants: real-world data from the Italian biomarker ATLAS database

Osimertinib exhibited meaningful differences in efficacy and resistance mechanisms across distinct ucEGFR mut, and ex19 delins showed comparable survival outcomes and resistance patterns to classical ex19 deletions, albeit with heterogeneous osimertinib sensitivity depending on the deletion–insertion starting codon.

G. Farinea, A. Mogavero, A. Vitale et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.